US Patent

US10758534 — Modulators of cystic fibrosis transmembrane conductance regulator

Method of Use · Assigned to Vertex Pharmaceuticals Inc · Expires 2035-10-06 · 9y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects compounds for the treatment of CFTR mediated diseases, such as cystic fibrosis, and related pharmaceutical compositions and methods.

USPTO Abstract

The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R 1 , R 2 , R 3 , W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3589 —
U-3589 —
U-3144 —
U-3144 —

Patent Metadata

Patent number
US10758534
Jurisdiction
US
Classification
Method of Use
Expires
2035-10-06
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Vertex Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.